This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: Assistance Publique-Hopitaux De Paris, Centre National De La Recherche Scientifique, Ecole Nationale Superieure De Chimie De Paris. Active years: 2023.
Company Filing History:
1 out of 331 
1 out of 5,383 
1 out of 13 
Years Active: 2023
Title: Claude Capron: Innovator in Thermosensitive Polymeric Hydrogels
Introduction
Claude Capron is a notable inventor based in Boulogne, France. He has made significant contributions to the field of biomedical engineering, particularly in the development of innovative treatments for cancer. His work focuses on the use of thermosensitive polymeric hydrogels, which have the potential to improve therapeutic outcomes for patients.
Latest Patents
Claude Capron holds a patent for "Immunomodulation after locoregional anti-tumoral treatment." This invention involves a thermosensitive polymeric hydrogel that comprises at least one thermosensitive copolymer, an aqueous solution, and a mucoadhesive excipient. The hydrogel is designed to include at least one immunostimulatory adjuvant, cytokine, chemokine, or heat shock protein. This innovative hydrogel is intended for use in the treatment of tumors or metastasis in subjects with cancer, particularly those with metastatic cancer. He has 1 patent to his name.
Career Highlights
Throughout his career, Claude Capron has worked with prestigious institutions such as the National Institute of Health and Medical Research and the Centre National de la Recherche Scientifique. His research has focused on developing advanced materials that can enhance cancer treatment efficacy.
Collaborations
Claude has collaborated with notable professionals in his field, including Robert Malafosse and Nathalie Mignet. These collaborations have contributed to the advancement of his research and the successful development of his patented technologies.
Conclusion
Claude Capron is a pioneering inventor whose work in thermosensitive polymeric hydrogels represents a significant advancement in cancer treatment. His innovative approach has the potential to improve patient outcomes and contribute to the ongoing fight against cancer.